Healthy volunteers help test safety of new brain drug
NCT ID NCT06753955
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-stage study tested a single dose of ART5803, a potential treatment for autoimmune encephalitis (brain inflammation caused by the body's own immune system), in 7 healthy adults. The goal was to check the drug's safety and how it interacts with IVIG, a common immune therapy. No treatment benefit was expected; the study simply gathered safety information to guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.